Trial Profile
Perioperative RAMucirumab in Combination With FLOT Versus FLOT Alone for reSEctable eSophagogastric Adenocarcinoma - RAMSES - a Phase II/III Trial of the AIO
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms RAMSES
- 01 Jul 2023 Results published in the International Journal of Cancer
- 08 Jul 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Primary endpoint has been met (Phase II: Rate of pathological complete or subtotal responses (pCR/pSR): assessed according to Becker remission criteria) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology